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Emergence of NDM-1-producing Acinetobacter
pittii  in Brazil
Sir,
The  New Delhi metallo--lactamase (NDM), initially reported
in Klebsiella pneumoniae and Escherichia coli, is  now disseminated
worldwide mostly among Enterobacteriaceae [1]. The NDM car-
bapenemase has also been described in  Acinetobacter baumannii,
but only in sporadic cases in countries such as China, India, Egypt,
Germany, Israel and, more recently, Brazil [1,2]. Noteworthy, recent
studies reported NDM-producers among non-baumannii Acineto-
bacter spp., which may  also be human pathogens. Here we report
the ﬁrst case of NDM-1-producing Acinetobacter pittii in Brazil.
A  66-year-old male patient with bladder carcinoma was admit-
ted for radical cystectomy to a  900-bed tertiary care hospital in
Porto Alegre, Southern Brazil, on 25 February 2013. Fifteen days
later he presented an intestinal subocclusion and fever. Compu-
terised tomography (CT) of the abdomen showed the presence of
a collection in pelvis, which was drained surgically. This puru-
lent secretion was cultured and a K. pneumoniae was identiﬁed
(VITEK® 2 system; bioMérieux, La Balme-les-Grottes, France).
Urine was also cultured and revealed the presence of Candida
sp. (50 000 CFU/mL) and Acinetobacter sp. (>100 000 CFU/mL). The
patient was treated with intravenous meropenem 500 mg every
12 h for 7 days, followed by cefepime 1 g every 24 h (doses
adjusted to impaired renal function). Three subsequent urine cul-
tures obtained 11, 28 and 44 days after the ﬁrst culture were
negative for Acinetobacter sp. The patient was therefore considered
colonised by Acinetobacter sp. After 90 days the patient improved
and was discharged from the hospital.
The Acinetobacter sp. isolate MP was identiﬁed as A. pittii by
matrix-assisted laser desorption/ionisation time-of-ﬂight (MALDI-
TOF) (Bruker Daltonik, Bremen, Germany), gyrB multiplex PCR and
16S rRNA gene sequencing. Minimum inhibitory concentrations
(MICs) of -lactams, aminoglycosides, ciproﬂoxacin, fosfomycin,
chloramphenicol, tigecycline, colistin and polymyxin B were
determined (Etest® and microdilution method) and showed
that the isolate was resistant to all -lactams (with the excep-
tion of aztreonam), including carbapenems (MICs of imipenem,
ertapenem, doripenem and meropenem >32 g/mL). The isolate
remained  susceptible to amikacin, gentamicin, tigecycline, colistin,
polymyxin B, ciproﬂoxacin and chloramphenicol. Carbapenemase
genes were searched by real-time PCR (blaOXA-48,  blaKPC,  blaIMP,
blaVIM and blaGES) and multiplex PCR (blaOXA-23-like,  blaOXA-40-like,
blaOXA-58-like and blaOXA-143). A positive signal was obtained only
for the blaNDM gene, and sequencing identiﬁed the blaNDM-1 gene.
To identify the location of this gene, electrotransformation assays
were attempted using plasmid DNA extracts from A. pittii isolate
MP using A. baumannii CIP7010 and E. coli TOP10 as recipients.
Transfer of the blaNDM-1 gene by electrotransformation into these
two recipient strains remained unsuccessful, suggesting that the
gene might be chromosomally located in A. pittii MP,  as reported
in A. baumannii [3].
The  genetic environment of the blaNDM-1 gene was  determined
by PCR mapping as described [3] and insertion sequence ISAba125
was identiﬁed upstream of the blaNDM-1 gene. However, attempts
to identify another copy of ISAba125 downstream of blaNDM-1
remained unsuccessful, suggesting that the blaNDM-1 gene might be
part of a  truncated Tn125 transposon, as previously reported in A.
baumannii [3]. Multilocus sequence typing (MLST) was  performed
according to the Institute Pasteur scheme (http://www.pasteur.fr)
and  A. pittii isolate MP  was  identiﬁed as ST119. Interestingly,
two blaNDM-positive A. pittii isolates were recently identiﬁed in
Paraguay [4], a  neighbouring country of Brazil, but those isolates
belonged to  ST320 and ST321. The only reports of A. pittii ST119
isolates are from Japan, with isolates producing the carbapenemase
IMP-19 [1].
Identiﬁcation of blaNDM-positive non-baumannii Acinetobacter
spp. is  now increasingly reported worldwide, concomitantly with
those of blaNDM-positive A. baumannii isolates. There are few
reports of NDM-producing A. pittii, being from China, Turkey and
recently Paraguay. This is of particular concern considering that
Acinetobacter sp. may  (i) act as reservoirs for blaNDM genes in
non-human settings, as recently shown in  several Chinese studies
with identiﬁcation of NDM-1-producers among Acinetobacter cal-
coaceticus and Acinetobacter junii from environmental samples from
livestock farms [1], Acinetobacter johnsonii from hospital sewage
[1] and Acinetobacter lwofﬁi from chickens [1], but also (ii) act as a
source of blaNDM genes then horizontally transferred to  enterobac-
terial species as evidenced [5].
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